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Abstract 
Humans encode seven APOBEC3 proteins (A–H), with A3G, 3F and 3H as the major factors restricting HIV‑1 replica‑
tion. HIV‑1, however, encodes Vif, which counteracts A3 proteins by chaperoning them to the proteasome where 
they are degraded. Vif polymorphisms found in HIV‑1s isolated from infected patients have varying anti‑A3G potency 
when assayed in vitro, but there are few studies demonstrating this in in vivo models. Here, we created Friend murine 
leukemia viruses encoding vif alleles that were previously shown to differentially neutralize A3G in cell culture or that 
were originally found in primary HIV‑1 isolates. Infection of transgenic mice expressing different levels of human A3G 
showed that these naturally occurring Vif variants differed in their ability to counteract A3G during in vivo infection, 
although the effects on viral replication were not identical to those seen in cultured cells. We also found that the 
polymorphic Vifs that attenuated viral replication reverted to wild type only in A3G transgenic mice. Finally, we found 
that the level of A3G‑mediated deamination was inversely correlated with the level of viral replication. This animal 
model should be useful for studying the functional significance of naturally occurring vif polymorphisms, as well as 
viral evolution in the presence of A3G.
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Apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like (A3) proteins are cytidine deaminases 
that play important roles in antiviral intrinsic immunity. 
Humans encode seven genes (A3A–A3H), and several of 
these potently restrict HIV-1 by causing G-to-A hyper-
mutation of the viral genome as well as by deaminase-
independent mechanisms [1]. HIV and most other len-
tiviruses, however, contain Viral Infectivity Factor (vif) 
genes, which encode proteins that counteract the antivi-
ral activity of A3 proteins [2–4]. In cells producing vif-
deficient HIV-1, A3 proteins are packaged into progeny 
virions via interaction with the nucleocapsid (NC) pro-
tein and viral RNA. However, in cells producing wildtype 
virus, Vif binds A3D, A3F, A3G and certain A3H hap-
lotypes. Although efficiencies vary, Vif binding targets 
these proteins for ubiquitinylation and degradation in 
the proteasome through interactions with a number of 
host cellular factors, including CBF-β, Cul5 and elongins, 
thereby preventing their packaging and overcoming the 
anti-viral activity [5–12]. In  vitro studies have shown 
that naturally occurring polymorphisms, in many cases 
resulting in single amino acid residue changes, enhance 
or attenuate the ability of Vif to interact with and antago-
nize A3G as well as other A3s. Furthermore, it has been 
shown that the anti-A3G activities of Vifs found in HIV-
1s isolated from Elite Controllers are significantly lower 
than those derived from non-controllers, suggesting that 
this host anti-viral activity is important for the effective 
control of infection in  vivo [13]. It has also been sug-
gested that partial neutralization of A3G may increase 
HIV-1 sequence diversity and promote the emergence of 
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immune escape variants as well as variants with altered 
co-receptor usage [9, 14–16]. Due to the potential role of 
A3G in the diversification of HIV-1, as well as the interest 
in the development of inhibitors that target the A3G–Vif 
interaction, it is important to characterize the impact of 
vif polymorphisms on A3G-mediated virus restriction 
in vivo.
Our lab pioneered the study of A3 genes in vivo using 
transgenic mice expressing individual human A3 proteins 
[17]. Two A3G transgenic mice strains were developed on 
a mouse A3 knockout (KO) background, expressing high 
and low levels of the transgene in the absence of a mouse 
A3 ortholog; importantly, the level of A3G expression 
in the A3Ghigh strain was similar to that seen in human 
peripheral blood mononuclear cells, while the levels in 
the A3Glow strain were approximately 30-fold lower [17]. 
Our previous work demonstrated potent inhibition of 
retrovirus replication by A3G in these mice and showed 
that the level of virus replication was proportional to the 
level of A3G expression and cytidine deamination of the 
viral genomes. Furthermore, we showed that A3G-medi-
ated restriction could be overcome in  vivo by a Friend 
murine leukemia virus (F-MLV) encoding the HIV-1 
NL4-3 vif gene, derived from a lab-adapted HIV-1 molec-
ular clone; expression of Vif led to degradation of A3G 
in splenic extracts, decreased packaging into virions and 
increased cytidine deamination of viral genomes [17]. 
The in vivo cellular targets of MLV infection are similar 
to HIV-1, namely sentinel cells, such as macrophages and 
dendritic cells, and lymphocytes [18–20].
Here, we tested whether our A3G transgenic mouse 
models could be used to assess the effect of naturally 
occurring vif polymorphisms on the ability of this acces-
sory protein to counteract host A3G restriction [21, 
22]. For this, we first developed five F-MLV-vif variant 
viruses that encoded vif alleles that differ only at a sin-
gle amino acid position from the NL4-3 HIV-1 molecular 
clone; these polymorphisms were previously identified in 
HIV-1 strains identified in patient PBMCs (Fig.  1a) [21, 
22]. The amino acid residue changes include three found 
in non-progressors (W11R, Y40H and G143R), one that 
arose after infection of non-progressor PBMCs with 
patient-derived HIV-1s (K22E) and one found as a com-
mon mutation in patients who failed highly active anti-
retroviral therapy (K22H). Previous cell culture studies 
revealed that Y40H, K22E and K22H had reduced abil-
ity to counteract A3G, while W11R and G143R were as 
active as the NL4-3 Vif. To introduce these variant amino 
acids into F-MLV, the NL4-3 vif sequence was cloned into 
pcDNA3.1/myc-his (Invitrogen) and the specific amino 
acid changes were introduced by site-directed mutagen-
esis (QuikChange II XL Site-Directed Mutagenesis Kit, 
Agilent). The mutated vif genes were then inserted into 
a plasmid containing a replication-competent F-MLV-2A 
molecular clone, as previously described [23] (Fig.  1a). 
Virus stocks were produced by transfection of 293T cells 
and supernatants were collected 48  h post-transfection. 
Amplification of viruses to generate high-titer stocks 
was performed as described [23]. Viral RNA from these 
stocks was PCR-amplified to ensure that the vif gene was 
retained during passage; amplification of the same RNAs 
with env primers served as controls (Fig.  1b) and the 
vif regions were sequenced to ensure that the targeted 
mutations were retained (not shown). Additionally, we 
examined Vif levels after transfection of the viral con-
structs into 293T virus producer cells by western blot and 
showed that each of the mutants was expressed at similar 
levels in virus-producer cells (Fig. 1c).
As the replication efficiency of the F-MLV variant 
viruses could differ due to the insertion of vif or the 
introduction of specific mutations, we first assessed the 
replication kinetics of these viruses in culture over a 
9-day period. All vif-containing viruses replicated with 
similar kinetics (not shown), with peak viremia observed 
at 6 days post-infection (dpi) (Fig. 1d). Wildtype F-MLV 
(F-MLV-2A) grew to significantly higher titers at 6 dpi, 
indicating that insertion of the HIV-1 vif gene attenu-
ated viral replication. However, the introduction of sin-
gle amino acid residue changes into the NL4-3 vif in 
F-MLV did not significantly affect the replication of any 
of the F-MLV-vif variants (Fig. 1d). Similar results were 
obtained when the viruses were inoculated into A3 KO 
mice (Fig. 1e).
Next, we compared infection of A3 KO and both 
human A3G transgenic mouse lines with the differ-
ent F-MLV-Vif variants as well as F-MLV-2A. Because 
the range of basal expression of A3G at the RNA level 
in PBMCs from HIV-1 uninfected individuals has been 
reported to be >tenfold [24], we tested the efficacy of 
each of the variant Vifs in both A3Ghigh and A3Glow 
mice, thereby mimicking the variation in A3G expression 
seen in humans. Two-day old pups of each strain were 
injected intraperitoneally with 104 PFU of each virus. 
Spleens were collected at 16 dpi and infection levels were 
determined by infectious center (IC) assays using a focal 
immunofluorescence assay, as previously described [17].
As shown previously, A3G restricted F-MLV-2A pro-
portionally to its level of expression, with infection 
reduced by half a log and 1 log in A3Glow and A3Ghigh 
mice, respectively, relative to infection in KO mice. By 
contrast, as we showed previously, F-MLV-Vif (NL4-3) 
replication was inhibited in the A3Ghigh strain by only 
half a log, while no differences were observed between 
A3Glow and KO mice, suggesting that the NL4-3 Vif fully 
compensated low levels of A3G-mediated restriction 
(Fig. 2a) [25]. F-MLV-G143R behaved similarly to NL4-3; 
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this was also seen in the in  vitro studies [21]. However, 
several other mutants examined in  vivo showed dif-
ferent results than in  vitro. The K22E and K22H muta-
tions which were previously shown to weakly counteract 
A3G’s anti-Vif activity, had no anti-viral activity in either 
the A3Glow or A3Ghigh mice in  vivo, producing infec-
tion levels similar to the vif-virus F-MLV-2A (Fig.  2a) 
[21, 22]. In fact, K22E was even more attenuated in vivo 
than F-MLV-2A in the A3Glow mice, but this may reflect 
a reduced ability to replicate (Fig.  1e). Y40H, which 
appeared to encode a weaker Vif than NL4-3 Vif in vitro, 
instead was able to counteract A3G in  vivo similar to 
NL4-3 Vif, although there was somewhat greater variabil-
ity in infection levels in individual mice. Mutant W11R 
did not show any inhibition by A3G, even in A3Ghigh 
mice, although in vitro it behaved similarly to NL4-3 Vif. 
This suggests that the W11R mutation might confer Vif 
with a more potent A3G neutralization ability than the 
NL4-3 allele.
Since the NL4-3 vif counteracted A3G in the context of 
F-MLV, we used this transgenic mouse model to exam-
ine the vif genes of a pair of matched transmitted founder 
(TF) and 6  months (6-mo) consensus infectious molec-
ular clones (IMC) from a longitudinally studied subject 
(CH470), which differed in their sensitivity to type 1 
interferons [26]. Since these two IMCs encoded Vif pro-
teins that differed in 3 amino acids, we hypothesized that 
two non-conservative changes (K19N/Q136H) might be 
responsible for altered A3G counteraction. To test this, 
we cloned the TF and K19N/Q136H mutant vif alleles 
NL4-3       G143R      K22E      K22H        Y40H     W11R
vif
env
a
d
b e
c
β-acn
vif
Fig. 1 a Top a plasmid encoding the full‐length replication‐competent clone Friend MLV was modified by adding a 2A peptide sequence (P2A) 
from picornaviruses, in frame with the C terminus of the envelope gene, followed by a Not1 restriction site and a stop codon. The vif gene was 
cloned in frame into the Not1 site to generate F‑MLV‐2A‐vif. Bottom the Vif protein sequence of the NL4‑3 molecular clone is shown. The single 
amino acid residue changes used for this study are highlighted in red at positions a11, a22, a40, and a143. b PCR of RNA isolated from viruses 
propagated in vitro using vif‑ and env‑specific primers. c Western blot analysis of cell extracts from virus‑producer cells. 293T cells were co‑trans‑
fected with the indicated F‑MLV‑vif virus and 24 h post‑transfection, equal amounts of cell lysates were analyzed by Western blot, using anti‑Vif and 
anti‑β‑actin antisera. d Replication of F‑MLV‑Vif variants in vitro. Mus dunni cells were infected at an MOI = 0.1. Supernatants were collected 6 days 
post‑infection and viral titers were measured by plaque assay. The data represent the average of 3 experiments, with the error bars showing stand‑
ard deviations. e 2 day‑old A3 KO mice were infected with 104 PFU of each virus intraperitoneally. Splenocytes were isolated at 16 dpi and tenfold 
dilutions of these cells were co‑cultured with Mus dunni cells for 3 days. Viral titers were assessed by plaque assay. The data represent the average of 
at least 5 mice per group, with the error bars showing standard deviations. ***P ≤ 0.001; NS not significant (one‑way ANOVA)
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into the F-MLV-2A backbone and examined their func-
tion in vivo. Similar to what was seen for F-MLV-NL4-3, 
mice bearing the CH470-derived vifs replicated less effi-
ciently than the vif-parent (not shown). Two different 
virus inocula were used to infect the different mice, 103 
and 104 PFU/mouse. Both CH470 vif containing viruses 
replicated to levels similar to that seen with the virus 
containing NL4-3 Vif after inoculation with either virus 
amount, fully counteracting A3G in mice with low level 
expression and partially restoring infectivity in mice with 
high level expression (Fig.  2b). No difference was seen 
between the TF and K19N/Q136H mutant vif-containing 
viruses, indicating that these particular amino acid 
changes did not alter Vif/A3G interactions. Thus, the 
observed differences in IFN sensitivity of the CH470 TF 
and 6-mo IMCs are unlikely to be explained by differen-
tial A3G counteraction.
To ensure that the viruses propagated in vivo retained 
vif, we PCR-amplified DNA isolated from infected sple-
nocytes and showed that all of the virus populations 
had vif-containing viruses (Fig.  3a). We also cloned 
and sequenced the vifs from the different viruses in 
A3KO, A3Ghigh and A3Glow mice (Table  2). Interest-
ingly, we found that the two most attenuated viruses in 
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Fig. 2 Relative virus titers in the spleens of A3G transgenic mice after infection of with F‑MLV‑Vif variants. a Newborn A3 knock‑out or A3G 
transgenic mice were infected intraperitoneally with 104 PFU of the different F‑MLV‑Vif variants. Spleens were collected 16 days post infection and 
splenocytes were isolated for assessment of viral levels by infectivity assays on Mus dunni fibroblasts. b Newborn mice were also infected with 103 
(left) or 104 (right) PFU of F‑MLV‑VifTF or F‑MLV‑VifK19N/Q136H. Each point represents the titer obtained from each individual mouse normalized to the 
average titer measured in the spleens of A3 KO mice infected with the same virus (A3G/KO). Each point represents the viral load measured from an 
individual mouse; the mean (horizontal bar) and standard deviation for each group is shown. The transgenic mice were derived from 2 to 4 litters 
each; the knockout mice are the littermates of the transgenic mice. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; NS not significant (Mann–Whitney T test)
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the presence of A3G, K22E and K22H, showed reversion 
to wild type vif in both the A3Glow and A3Ghigh strains, 
while for Y40H, which was attenuated only in A3Ghigh 
mice, we found revertants in this but not the A3Glow 
strain (Fig. 3b; Table 2). No reversion was seen with the 
fully infectious W11R or G143R viruses.
Sequencing of F-MLV env as well as the various vifs 
after infection showed that, as described in previous 
in vitro studies and patient samples, the level of restric-
tion by A3G was proportional to the level of G-to-A 
hypermutation in the virus (Tables 1, 2). As we reported 
previously, the majority of the G-to-A changes were in 
the GG motif (not shown) [17]. NL4-3, G143R, W11R, 
all potent inhibitors of A3G, showed less deamina-
tion overall in both mouse strains, while 2A, K22E and 
K22H, showed more deamination and introduced more 
stop codons than the other viruses, corresponding to the 
absence or lack of Vif activity. Y40H, which showed an 
intermediate phenotype in vitro, also had an intermedi-
ate level of deamination (Tables 1, 2).
In our panel of F-MLV-Vif polymorphisms, we found 
viruses that display a range of anti-A3G activity. Infection 
of transgenic mice with F-MLV encoding the NL4-3 vif 
and 2A agrees with our previous results, with both A3G 
strains restricting 2A, but only A3Ghigh restricting NL4-
3. In contrast to our previous study where F-MLV-2A 
infection in A3Glow mice was decreased by more than 1 
log, here we saw only about a fivefold difference in infec-
tion compared to the A3 KO mice. This is likely due to 
the higher dose of virus used (10 times higher than our 
previous experiments). Interestingly, W11R Vif showed 
a stronger phenotype than NL4-3 Vif, as the virus was 
able to overcome A3G even in the A3Ghigh mice (Fig. 2), 
although the G-to-A deamination frequency was similar 
(Table 1). This is in contrast to previous studies in tissue 
culture, where W11R infection was identical to that seen 
with NL4-3. K22E, however, showed a weaker phenotype 
than was seen previously, being restricted by A3G even 
at low expression levels and exhibiting high levels of cyti-
dine deamination. These differences may be due to the 
level of A3G expression or to the cell type in which A3G 
is expressed; the cellular targets of infection in the trans-
genic mice are likely similar to the natural targets of HIV 
infection in humans (e.g. sentinel and lymphoid cells).
Humanized mice infected with HIV-1 have also been 
used to study A3–Vif interactions in vivo [27, 28]. Similar 
to these studies, which showed that HIV proviral DNA 
is deaminated, even in viruses containing vif, we found 
that Vif in F-MLV decreased A3G deamination in pro-
portion to transgene expression (Tables 1, 2). Sub-lethal 
hypermutation by A3 proteins has been suggested to play 
a role in the diversification of the HIV-1 genome. Poly-
morphisms in Vif, readily identifiable in HIV-infected 
patients, have been shown to partially neutralize A3G 
in  vitro, and this might provide the virus with a novel 
mechanism for diversification. Our transgenic mice rep-
resent a unique model system to test these hypotheses, as 
well as an in vivo model for assessing the efficacy of anti-
viral drugs that target A3G–Vif interactions.
There are other A3 proteins, such as A3F, that also are 
counteracted by Vif and which have been implicated in 
restricting HIV-1 infection in humanized mice [28]. The 
construction of A3F- and other human A3-expressing 
transgenic mice would also permit the testing of drugs 
that target specific A3–Vif interactions. One advantage 
of the transgenic mice is that individual A3 proteins can 
be studied in isolation compared to humanized mice and 
therefore the interaction of different Vifs with individual 
A3 proteins can be readily distinguished both in the pres-
ence and absence of drugs that counteract these interac-
tions. Since we also showed previously that Vif expressed 
in the context of MLV leads to APOBEC3G degradation in 
NL43 W11R K22E K22H Y40H G143R
a
b
Y40H: CAC (H)  → TAT (Y)
K22E: GAG (E) → AAA (K); GAG (E) → AAG (K)
K22H: CAC (H) → AAA (K)
Fig. 3 Vif sequences are retained in viruses passaged in vivo. PCR analysis. a DNA isolated from the spleens of the mice infected with the different 
viruses was PCR‑amplified with primers flanking vif (5′‑atggaaaacagatggcaggt‑3′/5′‑ctagtgtccattcattgta‑3′). b Sequences of the revertant viruses 
found in the Y20H‑, K22E‑ and K22H‑infected mice
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the transgenic mice, these mice might be useful for testing 
compounds that target Vif-EloC/B interactions [17].
We also found reversion of F-MLV-Vif viruses which 
were highly attenuated for infection only in the A3G-
expressing mice. Although we only allowed infection to 
proceed in these experiments for 16  days, we showed 
previously that MLV infection can be followed in  vivo 
for 6  weeks post-infection [17]. Indeed, we have found 
that the majority of the A3Glow transgenic mice main-
tain low virus loads for at least 7 months post-infection 
and do not succumb to leukemogenesis (not shown); it is 
likely that the A3Ghigh mice will be even more resistant 
to virus-induced disease. Thus, these mice are likely to be 
useful to long-term studies of viral escape from host anti-
viral factors, as well as virus diversification.
In summary, using novel human A3G transgenic mouse 
models that express varying levels of A3G as is seen in 
humans, this study clearly demonstrates that polymor-
phic vif alleles can have differential anti-A3G activity 
in vivo.
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Table 2 Mutation frequencies in  env of  F-MLV-Vif proviruses bearing different Vif variants in  splenic DNA of  infected 
APOBEC3 KO, A3Ghigh and A3Glow transgenic mice
Analysis was performed on DNA cloned from a subset of the infected mice in Fig. 2 (3–4 mice/group; 10–15 sequences/mouse). F-MLV has a total of 58 GG motifs in 
the 586 bp region that was sequenced
FMLV-2A NL43 W11R K22E
KO A3GLow A3GHigh KO A3GLow A3GHigh KO A3GLow A3GHigh KO A3GLow A3GHigh
#G to A 7 27 116 1 2 12 1 1 18 5 57 63
#other 37 19 43 67 28 71 13 6 12 26 34 49
#mice 3 3 3 3 3 4 3 4 3 3 3 3
#clones 42 40 41 42 41 53 49 42 45 50 45 48
#bp 24,612 23,440 24,026 24,612 24,026 31,058 28,714 22,268 26,370 29,300 26,370 28,128
G to A freq. ×10−3 0.28 1.15 4.83 0.04 0.08 0.39 0.03 0.04 0.68 0.17 2.16 2.24
Other freq. ×10−3 1.50 0.81 1.79 2.72 1.17 2.29 0.45 0.27 0.46 0.89 1.29 1.74
#stop codons 2 4 46 0 1 4 0 0 7 0 15 31
K22H Y40H G143R
KO A3GLow A3GHigh KO A3GLow A3GHigh KO A3GLow A3GHigh
#G to A 3 29 62 0 10 27 2 7 9
#other 22 28 49 18 21 5 11 13 10
#mice 3 3 3 3 4 3 4 3 3
#clones 44 45 46 45 52 41 41 41 39
#bp 25,784 26,370 26,956 26,370 30,472 24,026 24,026 24,026 22,854
G to A freq. ×10−3 0.16 1.10 2.30 0.00 0.33 1.12 0.08 0.29 0.39
Other freq. ×10−3 0.85 1.06 1.82 0.68 0.69 0.21 0.46 0.54 0.44
#stop codons 0 14 25 0 0 7 1 1 1
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